Nerivio® | REN Wearable for Migraine by Theranica

Nerivio is a REN wearable for acute & preventive migraine treatment (8+), with or without aura, covered by Medicaid and commercial insurance.

Nerivio is a REN wearable for acute & preventive migraine treatment (8+), with or without aura, covered by a broad range of commercial health plans.

The first pivotal trial for REN didn’t just test a new device, it marked a shift in acute migraine treatment. By activating the body’s own descending pain inhibitory pathways through upper-arm stimulation, REN delivered meaningful relief without the systemic risks of pharmacologic therapies. In the study, [1] 66.7% of participants achieved pain relief at 2 hours with REN versus 38.8% with sham, and benefits persisted at 48 hours. Consistency was strong too, with 62.6% achieving relief in at least half their attacks. These results laid the foundation for today’s broadening adoption of drug-free migraine care and demonstrate how neuroscience-informed, non-invasive treatment can expand options for patients. Read the full blog for more insights. https://lnkd.in/dqaqYvaA [1] Yarnitsky et al., Headache, 2019 #MigraineTreatment #DrugFree #Neuromodulation

Before FDA clearance, before countless treatments, researchers asked a simple question: could a central pain-inhibiting signal activated peripherally (far from the head) provide meaningful relief at #migraine onset? A 2015 randomized, sham-controlled trial provided early answers. [1] Among participants: * Up to 48% achieved ≥50% pain reduction at 2 hours with the most intense stimulation protocols * 64% were classified as responders across their treated attacks * Timing was critical: starting treatment within 20 minutes of onset nearly doubled pain reduction compared with later use * Safety and tolerability: No device-related adverse events; most rated the treatment as pleasant or neutral The study highlighted REN’s central mechanism of activating the body’s own pain inhibitory pathways. Today, with years of research, real-world data, FDA clearance for ages 8+ and millions of treatments delivered, REN is a validated, practical, non-pharmacologic option for acute and preventive migraine care. https://lnkd.in/d5F5362c 1. Yarnitsky et al., Neurology, 2017

In migraine care, timing can be decisive. Our blog unpacks a large real-world analysis recently published in Cephalalgia that found initiating REN treatment within the first hour of an attack dramatically improves the likelihood of pain and symptom freedom. The message is clear: the best time to initiate is as early as possible. The second best time is now. #Migraine #Headache https://lnkd.in/eV9S2TMx

ENTs play a more important role in migraine care than many realize. Patients often present with sinus pressure, ear fullness or facial pain. Yet studies show that up to one-third of these cases meet #migraine criteria rather than ENT pathology. [1] Because migraine can manifest through otologic or sinus-related symptoms, otolaryngologists are uniquely positioned to identify and redirect care early, improving diagnosis and access to effective, drug-free options. As our understanding of migraine neurobiology deepens, collaboration between ENT and neurology continues to close diagnostic gaps and improve outcomes. https://lnkd.in/dcrRPNuZ [1] Abdelgafour et al., Egyptian Journal of Otolaryngology, 2025 #MigraineCare #ENT